株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アルツハイマー病およびパーキンソン病のための神経学的バイオマーカー市場:世界の機会分析と業界予測

Neurological Biomarkers Market for Alzheimers and Parkinsons Diseases - Global Opportunity Analysis and Industry Forecast, 2018-2025

発行 Allied Market Research 商品コード 660948
出版日 ページ情報 英文 90 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.65円で換算しております。
Back to Top
アルツハイマー病およびパーキンソン病のための神経学的バイオマーカー市場:世界の機会分析と業界予測 Neurological Biomarkers Market for Alzheimers and Parkinsons Diseases - Global Opportunity Analysis and Industry Forecast, 2018-2025
出版日: 2018年06月01日 ページ情報: 英文 90 Pages
概要

当レポートでは、世界のアルツハイマー病およびパーキンソン病のための神経学的バイオマーカー市場について調査し、市場の動向とアルツハイマー病およびパーキンソン病それぞれの市場動向、地域別動向をまとめています。

第1章 イントロダクション

  • レポートの内容
  • ステークホルダーの利益
  • 主な市場セグメント
  • 調査方法

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な有効戦略
  • 診断市場全体の規模
  • アルツハイマー病とパーキンソン病の発症率、死亡率、診断率、罹患率、治療率
  • ポーターズファイブフォース分析
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会

第4章 地域別アルツハイマー病市場

  • 概要
  • 米国
  • 欧州5カ国
  • その他の欧州諸国
  • 中国
  • アジア太平洋地域
  • その他の諸国

第5章 地域別パーキンソン病市場

  • 概要
  • 米国
  • 欧州5カ国
  • その他の欧州諸国
  • 中国
  • アジア太平洋地域
  • その他の諸国
図表

List of Tables

  • TABLE 01. KEY EXPERTS, NEUROLOGICAL BIOMARKERS MARKET
  • TABLE 02. TOTAL DIAGNOSTIC ALZHEIMER'S MARKET, BY DIAGNOSTIC TECHNIQUES, 2017-2025 ($MILLION)
  • TABLE 03. TOTAL DIAGNOSTIC PARKINSON'S MARKET, BY DIAGNOSTIC TECHNIQUES, 2017-2025 ($MILLION)
  • TABLE 04. STATISTICS FOR ALZHEIMER'S IN U.S.
  • TABLE 05. STATISTICS FOR ALZHEIMER'S IN EU5
  • TABLE 06. STATISTICS FOR ALZHEIMER'S IN REST OF EUROPE
  • TABLE 07. STATISTICS FOR ALZHEIMER'S IN CHINA
  • TABLE 08. STATISTICS FOR ALZHEIMER'S IN ASIA-PACIFIC
  • TABLE 09. STATISTICS FOR ALZHEIMER'S IN REST OF WORLD
  • TABLE 10. STATISTICS FOR PARKINSONS IN U.S.
  • TABLE 11. STATISTICS FOR PARKINSONS IN EU5
  • TABLE 12. STATISTICS FOR PARKINSONS IN REST OF EUROPE
  • TABLE 13. STATISTICS FOR PARKINSONS IN CHINA
  • TABLE 14. STATISTICS FOR PARKINSONS IN ASIA-PACIFIC
  • TABLE 15. STATISTICS FOR PARKINSONS IN REST OF WORLD
  • TABLE 16. NEUROLOGICAL BIOMARKERS MARKET FOR ALZHEIMERS, BY RGION, 2017-2025 ($MILLION)
  • TABLE 17. INDIVIDUALS DIAGNOSED WITH ALZHEIMER'S DISEASE IN EU5, 2012
  • TABLE 18. HUNGARY ALZHEIMER'S DISEASE PREVALENCE, BY AGE GROUP
  • TABLE 19. ESTIMATED COST INCURRED & NUMBER OF INDIVIDUALS WITH ALZHEIMERS DISEASE IN THE ASIA-PACIFIC REGION
  • TABLE 20. PREVALENCE OF ALZHEIMER'S DEMENTIA IN LATIN AMERICA, 2013
  • TABLE 21. NEUROLOGICAL BIOMARKERS MARKET FOR PARKINSONS, BY GEOGRAPHY, 2017-2025 ($MILLION)
  • TABLE 22. PREVALENCE OF PARKINSONS DISEASE IN ASIA-PACIFIC REGION, 2017
  • TABLE 23. PREVALENCE OF PARKINSONS DISEASE IN ASIA-PACIFIC REGION, 2017

List of Figures

  • FIGURE 01. TOP WINNING STRATEGIES, BY YEAR, 2014-2018*
  • FIGURE 02. TOP WINNING STRATEGIES, 2014-2018* (%)
  • FIGURE 03. TOP WINNING STRATEGIES, BY COMPANY, 2014-2018*
  • FIGURE 04. DIAGNOSTIC MARKET SIZE FOR ALZHEIMERS, 2017-2025 ($MILLION)
  • FIGURE 05. DIAGNOSTIC MARKET SIZE FOR PARKINSON'S, 2017-2025 ($MILLION)
  • FIGURE 06. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 07. HIGH BARGAINING POWER OF BUYERS
  • FIGURE 08. MODERATE THREAT OF SUBSTITUTION
  • FIGURE 09. MODERATE THREAT OF NEW ENTRANT
  • FIGURE 10. MODERATE COMPETITIVE RIVALRY
  • FIGURE 11. DRIVERS, RESTRAINTS, AND OPPORTUNITY: NEUROLOGICAL BIOMARKERS MARKET FOR ALZHEIMERS (AD) AND PARKINSONS (PD) DISEASES
  • FIGURE 12. PROJECTED NUMBER OF INDIVIDUALS IN THE U.S. WITH ALZHEIMERS, 2010 TO 2050
  • FIGURE 13. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN U.S.
  • FIGURE 14. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN EU5
  • FIGURE 15. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN REST OF EUROPE
  • FIGURE 16. NUMBER OF INDIVIDUALS IN CHINA WITH ALZHEIMERS, 1990 TO 2010
  • FIGURE 17. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN CHINA
  • FIGURE 18. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN ASIA-PACIFIC
  • FIGURE 19. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN ROW
  • FIGURE 20. PARKINSONS DISEASE BIOMARKERS MARKET IN U.S.
  • FIGURE 21. PARKINSONS DISEASE BIOMARKERS MARKET IN EU5
  • FIGURE 22. PARKINSONS DISEASE BIOMARKERS MARKET IN REST OF EUROPE
  • FIGURE 23. PARKINSONS DISEASE BIOMARKERS MARKET IN CHINA
  • FIGURE 24. PARKINSONS DISEASE BIOMARKERS MARKET IN ASIA-PACIFIC
  • FIGURE 25. PARKINSONS DISEASE BIOMARKERS MARKET IN ROW
目次
Product Code: LI_183555

The neurological biomarkers market for Alzheimer's disease generated a revenue of $2,636.7 million in 2017, registering a CAGR of 11.1% from 2018 to 2025. On the other hand, neurological biomarkers market for Parkinson's disease is expected to reach $2,457.4 million by 2025, registering a CAGR of 8.0%. Alzheimer's is included under dementia-associated conditions, and patients suffering from Alzheimer's face short-term memory loss, cognitive issues, and issues regarding behavior. In addition, Alzheimer is considered to be the most common form of dementia, and is known to account for the majority of the total dementia cases across the globe.

On the contrary, Parkinson's disease is the second most common neurodegenerative disorder across the globe. Patients suffering from Parkinson's disease face progressive deterioration of motor function that occurs over a period of time due to the loss of brain cells that produce dopamine. In-spite of being the second most common neurodegenerative disorder (after Alzheimer's), the market for this disease is relatively small, as the definite cause and treatment is unknown. This has opened up new avenues for the use neurological biomarkers. The neurological biomarkers market for Alzheimer's and Parkinson's diseases is studied across the U.S., EU5, rest of Europe, China, Asia-Pacific, and rest of the world (ROW).

KEY BENEFITS

  • The study provides an in-depth analysis of the neurological biomarkers market, with current trends and future estimations regarding Alzheimer's and Parkinson's.
  • A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Strategies recorded by the key players are analyzed thoroughly to understand the competitive outlook of the market.
  • Porter's Five Forces model is expected to interpret the bargaining power of suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.

KEY MARKET SEGMENTS

By Region

  • U.S.
  • EU5
  • Rest of Europe
  • China
  • Asia-Pacific
  • Row

KEY MARKET PLAYERS

  • Abbott Laboratories
  • Myriad RBM
  • Proteome Sciences
  • Thermo Fisher Scientific
  • Athena Diagnostics
  • Immunarray Pvt. Ltd.
  • Quanterix Corporation
  • Diagenic ASA
  • Psynova Neurotech
  • Bio-Rad Laboratories
  • The other players in the value chain include (profiles not included in the report)
  • Qiagen
  • AbaStar MDx
  • Acumen Pharmaceuticals
  • Abiant
  • Alseres Pharmaceuticals
  • Athena Diagnostics
  • Banyan Biomarkers
  • ProteoSys AG

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools & models
    • 1.4.4. Key assumptions
    • 1.4.5. Key experts

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Top winning strategies
  • 3.3. Overall Diagnostic Market Size
    • 3.3.1. Total diagnostic market size by diagnostic techniques
  • 3.4. Incidence, Mortality, Diagnosis Rate, Prevalence Rate and Treatment Rate for Alzheimers And Parkinsons Disease
    • 3.4.1. Incidence rate
    • 3.4.2. Mortality
    • 3.4.3. Diagnosis rate
    • 3.4.4. Prevalence rate
    • 3.4.5. Treatment rate
  • 3.5. Porters five forces analysis
  • 3.6. Market dynamics
    • 3.6.1. Drivers
      • 3.6.1.1. Increasing focus on developing cost-effective biomarker testing
      • 3.6.1.2. Rising demand for non-invasive diagnostic techniques for Alzheimers and Parkinsons
      • 3.6.1.3. Increase in the adoption of neurological biomarkers in clinical trials
    • 3.6.2. Restraints
      • 3.6.2.1. Stringent government regulations
      • 3.6.2.2. Emerging ethical issues regarding early diagnosis of Alzheimers and Parkinsons
    • 3.6.3. Opportunity
      • 3.6.3.1. Rise in the demand for personalized medicine

CHAPTER 4: ALZHEIMER'S DISEASE BIOMARKERS MARKET, BY REGION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. U.S.
    • 4.2.1. Key market trends and opportunities
    • 4.2.2. Market size and forecast
  • 4.3. EU5
    • 4.3.1. Key market trends and opportunities
    • 4.3.2. Market size and forecast
  • 4.4. Rest of Europe
    • 4.4.1. Key market trends and opportunities
    • 4.4.2. Market size and forecast
  • 4.5. China
    • 4.5.1. Key market trends and opportunities
    • 4.5.2. Market size and forecast
  • 4.6. Asia-Pacific
    • 4.6.1. Key market trends and opportunities
    • 4.6.2. Market size and forecast
  • 4.7. Rest of World (ROW)
    • 4.7.1. Key market trends and opportunities
    • 4.7.2. Market size and forecast

CHAPTER 5: PARKINSONS DISEASE BIOMARKERS MARKET, BY REGION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. U.S.
    • 5.2.1. Key market trends and opportunities
    • 5.2.2. Market size and forecast
  • 5.3. EU5
    • 5.3.1. Key market trends and opportunities
    • 5.3.2. Market size and forecast
  • 5.4. Rest of Europe
    • 5.4.1. Key market trends and opportunities
    • 5.4.2. Market size and forecast
  • 5.5. China
    • 5.5.1. Key market trends and opportunities
    • 5.5.2. Key market trends and opportunities
    • 5.5.3. Market size and forecast
  • 5.6. Asia-Pacific
    • 5.6.1. Key market trends and opportunities
    • 5.6.2. Market size and forecast
  • 5.7. ROW
    • 5.7.1. Key market trends and opportunities
    • 5.7.2. Market size and forecast
Back to Top